First Comprehensive Characterization of Lip Lymphoma: A Population-Based Study.

IF 2.8 4区医学 Q3 HEMATOLOGY

Acta Haematologica Pub Date : 2026-02-17 DOI:10.1159/000551039

Pierre Loap, Youlia Kirova

{"title":"First Comprehensive Characterization of Lip Lymphoma: A Population-Based Study.","authors":"Pierre Loap, Youlia Kirova","doi":"10.1159/000551039","DOIUrl":null,"url":null,"abstract":"Introduction: Lip lymphoma is an exceptionally rare extranodal lymphoma with limited data to guide clinical management. We conducted the first large-scale population-based analysis to characterize its epidemiology, treatment patterns, and outcomes.Methods: We identified all lip lymphoma cases (2000-2022) from the SEER database (17 registries). Patients were categorized as localized primary lip lymphoma (stage I) or lymphoma involving the lip area (stages II-IV).Results: Among 82 patients (median age 62 years, 54.9% female), age-adjusted incidence was 0.0459 per million per year. MALT lymphoma predominated (46.3%). With the median follow-up of 74.5 months, 21 deaths (25.6%) occurred, only 5 (6.1%) lymphoma related. Ten-year overall and cancer-specific survival rates were 72.7% and 92.6%, respectively. In multivariate analysis, age (HR 1.115/year, p < 0.001) and non-low-grade histology (HR 3.251, p = 0.043) independently predicted survival. All lymphoma-related deaths occurred in patients with aggressive or unknown histologies, none in confirmed low-grade B-cell lymphomas. No treatment strategy (surgery, radiotherapy, or systemic treatment) showed a significant superiority in terms of survival.Conclusion: Lip lymphoma demonstrates excellent prognosis, particularly for low-grade B-cell histologies. Age and histological grade represent principal prognostic factors guiding treatment strategies.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-9"},"PeriodicalIF":2.8000,"publicationDate":"2026-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13043128/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Haematologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000551039","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Lip lymphoma is an exceptionally rare extranodal lymphoma with limited data to guide clinical management. We conducted the first large-scale population-based analysis to characterize its epidemiology, treatment patterns, and outcomes.

Methods: We identified all lip lymphoma cases (2000-2022) from the SEER database (17 registries). Patients were categorized as localized primary lip lymphoma (stage I) or lymphoma involving the lip area (stages II-IV).

Results: Among 82 patients (median age 62 years, 54.9% female), age-adjusted incidence was 0.0459 per million per year. MALT lymphoma predominated (46.3%). With the median follow-up of 74.5 months, 21 deaths (25.6%) occurred, only 5 (6.1%) lymphoma related. Ten-year overall and cancer-specific survival rates were 72.7% and 92.6%, respectively. In multivariate analysis, age (HR 1.115/year, p < 0.001) and non-low-grade histology (HR 3.251, p = 0.043) independently predicted survival. All lymphoma-related deaths occurred in patients with aggressive or unknown histologies, none in confirmed low-grade B-cell lymphomas. No treatment strategy (surgery, radiotherapy, or systemic treatment) showed a significant superiority in terms of survival.

Conclusion: Lip lymphoma demonstrates excellent prognosis, particularly for low-grade B-cell histologies. Age and histological grade represent principal prognostic factors guiding treatment strategies.

查看原文本刊更多论文

首次全面表征唇淋巴瘤：一项基于人群的研究。

背景：唇部淋巴瘤是一种非常罕见的结外淋巴瘤，临床治疗资料有限。我们进行了第一次大规模的基于人群的分析，以表征其流行病学、治疗模式和结果。方法：我们从SEER数据库（17个注册中心）中确定所有唇部淋巴瘤病例（2000-2022）。患者分为局部原发性唇部淋巴瘤（LPLL， I期）和累及唇部的淋巴瘤（LIL， II-IV期）。结果：82例患者（中位年龄62岁，女性54.9%），年龄调整后的发病率为0.0459 /百万人/年。MALT淋巴瘤占多数（46.3%）。中位随访74.5个月，发生21例死亡（25.6%），仅有5例（6.1%）与淋巴瘤相关。十年总体生存率和癌症特异性生存率分别为72.7%和92.6%。结论：唇部淋巴瘤具有良好的预后，特别是对于低级别b细胞组织。年龄和组织学分级是指导治疗策略的主要预后因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Haematologica 医学-血液学

CiteScore

4.90

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： ''Acta Haematologica'' is a well-established and internationally recognized clinically-oriented journal featuring balanced, wide-ranging coverage of current hematology research. A wealth of information on such problems as anemia, leukemia, lymphoma, multiple myeloma, hereditary disorders, blood coagulation, growth factors, hematopoiesis and differentiation is contained in first-rate basic and clinical papers some of which are accompanied by editorial comments by eminent experts. These are supplemented by short state-of-the-art communications, reviews and correspondence as well as occasional special issues devoted to ‘hot topics’ in hematology. These will keep the practicing hematologist well informed of the new developments in the field.